Interleukins‐17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation

Adrien Guillot, Imène Gasmi, Arthur Brouillet, Yeni Ait‐Ahmed, Julien Calderaro, Isaac Ruiz, Bin Gao, Sophie Lotersztajn, Jean‐Michel Pawlotsky, Fouad Lafdil – 30 January 2018 – Liver progenitor cells (LPCs)/ductular reactions (DRs) are associated with inflammation and implicated in the pathogenesis of chronic liver diseases. However, how inflammation regulates LPCs/DRs remains largely unknown. Identification of inflammatory processes that involve LPC activation and expansion represent a key step in understanding the pathogenesis of liver diseases.

Targeting Pin1 by inhibitor API‐1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development

Wenchen Pu, Jiao Li, Yuanyuan Zheng, Xianyan Shen, Xin Fan, Jian‐Kang Zhou, Juan He, Yulan Deng, Xuesha Liu, Chun Wang, Shengyong Yang, Qiang Chen, Lunxu Liu, Guolin Zhang, Yu‐Quan Wei, Yong Peng – 30 January 2018 – Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, but there are few effective treatments. Aberrant microRNA (miRNA) biogenesis is correlated with HCC development. We previously demonstrated that peptidyl‐prolyl cis‐trans isomerase NIMA‐interacting 1 (Pin1) participates in miRNA biogenesis and is a potential HCC treatment target.

Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice

Jun Gong, Chun Fang, Peng Zhang, Pi‐Xiao Wang, Yixing Qiu, Li‐Jun Shen, Li Zhang, Xue‐Yong Zhu, Song Tian, Feng Li, Zhihua Wang, Zan Huang, Aibing Wang, Xiao‐Dong Zhang, Zhi‐Gang She – 30 January 2018 – Tumor progression locus 2 (TPL2), a serine/threonine kinase, has been regarded as a potentially interesting target for the treatment of various diseases with an inflammatory component. However, the function of TPL2 in regulating hepatocyte metabolism and liver inflammation during the progression of nonalcoholic fatty liver disease (NAFLD) is poorly understood.

A novel transforming growth factor beta‐induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma

Aude Merdrignac, Gaëlle Angenard, Coralie Allain, Kilian Petitjean, Damien Bergeat, Pascale Bellaud, Allain Fautrel, Bruno Turlin, Bruno Clément, Steven Dooley, Laurent Sulpice, Karim Boudjema, Cédric Coulouarn – 30 January 2018 – Intrahepatic cholangiocarcinoma (iCCA) is a deadly liver primary cancer associated with poor prognosis and limited therapeutic opportunities. Active transforming growth factor beta (TGFβ) signaling is a hallmark of the iCCA microenvironment. However, the impact of TGFβ on the transcriptome of iCCA tumor cells has been poorly investigated.

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings

Juan Berenguer, Ángela Gil‐Martin, Inmaculada Jarrin, Ana Moreno, Lourdes Dominguez, Marisa Montes, Teresa Aldámiz‐Echevarría, María J. Téllez, Ignacio Santos, Laura Benitez, José Sanz, Pablo Ryan, Gabriel Gaspar, Beatriz Alvarez, Juan E. Losa, Rafael Torres‐Perea, Carlos Barros, Juan V. San Martin, Sari Arponen, María T. de Guzmán, Raquel Monsalvo, Ana Vegas, María T. Garcia‐Benayas, Regino Serrano, Luis Gotuzzo, María Antonia Menendez, Luis M Belda, Eduardo Malmierca, María J. Calvo, Encarnación Cruz‐Martos, Juan J.

Liver atrophy and regeneration in noncirrhotic portal vein thrombosis: Effect of surgical shunts

Abdulrhman S. Elnaggar, Adam D. Griesemer, Stuart Bentley‐Hibbert, Robert S. Brown, Mercedes Martinez, Steven J. Lobritto, Tomoaki Kato, Jean C. Emond – 29 January 2018 – The goal of the study is to characterize the relationship between portal vein thrombosis (PVT) and hepatic atrophy in patients without cirrhosis and the effect of various types of surgical shunts on liver regeneration and splenomegaly. Patients without cirrhosis with PVT suffer from presinusoidal portal hypertension, and often hepatic atrophy is a topic that has received little attention.

Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole – 29 January 2018 – The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon‐free DAA treatment on all‐cause mortality in hepatitis C virus–infected patients without advanced liver disease.

Subscribe to